Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 19.20% is 11% above its 5-year average of 17.30%, around the middle of its 5-year range (12.13%–29.67%).
0.59% above its 12-month average of 19.09%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 19.01%.
EBITDA MARGIN
19.20%
EBITDA MARGIN AVG TTM
19.09%
EBITDA MARGIN AVG 3Y
18.95%
EBITDA MARGIN AVG 5Y
17.30%
EBITDA MARGIN AVG 10Y
15.66%
EBITDA MARGIN AVG 15Y
14.89%
EBITDA MARGIN AVG 20Y
13.98%
CURRENT VS TTM AVG
+0.59%
CURRENT VS 3Y AVG
+1.34%
CURRENT VS 5Y AVG
+11.01%
CURRENT VS 10Y AVG
+22.59%
CURRENT VS 15Y AVG
+28.91%
CURRENT VS 20Y AVG
+37.29%
UFP Technologies, Inc.
Market Cap
$2.34B
EBITDA Margin
19.20%
TTM Avg
19.09%
3Y Avg
18.95%
5Y Avg
17.30%
Market Cap
$2.35B
EBITDA Margin
-317.71%
TTM Avg
-346.77%
3Y Avg
-338.06%
5Y Avg
-349.04%
Market Cap
$2.36B
EBITDA Margin
39.11%
TTM Avg
36.80%
3Y Avg
16.06%
5Y Avg
-24.25%
Market Cap
$2.30B
EBITDA Margin
-31.49%
TTM Avg
-441.22%
3Y Avg
-377.50%
5Y Avg
-1549.50%
Market Cap
$2.38B
EBITDA Margin
-4.36%
TTM Avg
-3.80%
3Y Avg
-12.43%
5Y Avg
-17.77%
Market Cap
$2.28B
EBITDA Margin
26.92%
TTM Avg
28.50%
3Y Avg
31.74%
5Y Avg
29.80%
Market Cap
$2.43B
EBITDA Margin
-755.79%
TTM Avg
-753.93%
3Y Avg
-709.93%
5Y Avg
-1157.85%
Market Cap
$2.24B
EBITDA Margin
-37.02%
TTM Avg
-37.02%
3Y Avg
-37.02%
5Y Avg
-37.02%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| UFP Technologies, Inc. (UFPT) | $2.34B | 19.20% | 19.09% | 18.95% | 17.30% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.35B | -317.71% | -346.77% | -338.06% | -349.04% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | 39.11% | 36.80% | 16.06% | -24.25% |
| Disc Medicine, Inc. (IRON)vs › | $2.37B | N/A | N/A | N/A | N/A |
| Liquidia Corporation (LQDA)vs › | $2.30B | -31.49% | -441.22% | -377.50% | -1549.50% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.38B | -4.36% | -3.80% | -12.43% | -17.77% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.28B | 26.92% | 28.50% | 31.74% | 29.80% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.43B | -755.79% | -753.93% | -709.93% | -1157.85% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.24B | -37.02% | -37.02% | -37.02% | -37.02% |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.49B | 7.61% | 16.05% | 16.23% | 20.37% |
Gross Margin
28.5%
EBITDA Margin
19.2%
Operating Margin
15.3%
Net Margin
11.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 19.01% |
| 2026-03-31 | 18.31% |
| 2025-12-31 | 20.72% |
| 2025-09-30 | 18.18% |
| 2025-06-30 | 19.21% |
| 2025-03-31 | 18.74% |
| 2024-12-31 | 18.68% |
| 2024-09-30 | 19.83% |
| 2024-06-30 | 19.04% |
| 2024-03-31 | 18.02% |
| 2023-12-31 | 15.47% |
| 2023-09-30 | 17.74% |
| 2023-06-30 | 19.86% |
| 2023-03-31 | 15.98% |
| 2022-12-31 | 14.93% |
| 2022-09-30 | 29.67% |
| 2022-06-30 | 16.45% |
| 2022-03-31 | 13.16% |
| 2021-12-31 | 12.13% |
| 2021-09-30 | 14.03% |
| 2021-06-30 | 16.41% |
| 2021-03-31 | 15.16% |
| 2020-12-31 | 15.49% |
| 2020-09-30 | 13.36% |
| 2020-06-30 | 11.91% |
| 2020-03-31 | 14.79% |
| 2019-12-31 | 17.50% |
| 2019-09-30 | 16.62% |
| 2019-06-30 | 16.73% |
| 2019-03-31 | 15.37% |
| 2018-12-31 | 14.80% |
| 2018-09-30 | 16.38% |
| 2018-06-30 | 15.73% |
| 2018-03-31 | 10.24% |
| 2017-12-31 | 9.46% |
| 2017-09-30 | 10.86% |
| 2017-06-30 | 14.07% |
| 2017-03-31 | 12.41% |
| 2016-12-31 | 10.36% |
| 2016-09-30 | 14.62% |
| 2016-06-30 | 14.71% |
| 2016-03-31 | 8.90% |
| 2015-12-31 | 11.62% |
| 2015-09-30 | 12.26% |
| 2015-06-30 | 12.81% |
| 2015-03-31 | 10.95% |
| 2014-12-31 | 10.35% |
| 2014-09-30 | 11.46% |
| 2014-06-30 | 11.47% |
| 2014-03-31 | 12.50% |
| 2013-12-31 | 18.37% |
| 2013-09-30 | 15.82% |
| 2013-06-30 | 15.73% |
| 2013-03-31 | 11.66% |
| 2012-12-31 | 16.22% |
| 2012-09-30 | 14.96% |
| 2012-06-30 | 14.94% |
| 2012-03-31 | 13.68% |
| 2011-12-31 | 15.95% |
| 2011-09-30 | 12.49% |
| 2011-06-30 | 15.01% |
| 2011-03-31 | 14.61% |
| 2010-12-31 | 16.53% |
| 2010-09-30 | 14.98% |
| 2010-06-30 | 14.96% |
| 2010-03-31 | 11.35% |
| 2009-12-31 | 17.70% |
| 2009-09-30 | 11.25% |
| 2009-06-30 | 7.81% |
| 2009-03-31 | 5.89% |
| 2008-12-31 | 9.57% |
| 2008-09-30 | 10.07% |
| 2008-06-30 | 11.99% |
| 2008-03-31 | 9.72% |
| 2007-12-31 | 14.63% |
| 2007-09-30 | 9.65% |
| 2007-06-30 | 10.50% |
| 2007-03-31 | 7.67% |
| 2006-12-31 | 9.93% |
| 2006-09-30 | 7.42% |
| 2006-06-30 | 8.93% |
| 2006-03-31 | 8.26% |
| 2005-12-31 | 7.07% |
| 2005-09-30 | 3.55% |
| 2005-06-30 | 7.19% |
| 2005-03-31 | 6.57% |
| 2004-12-31 | 8.37% |
| 2004-09-30 | 6.15% |
| 2004-06-30 | 6.76% |
| 2004-03-31 | 5.60% |
| 2003-12-31 | -4.53% |
| 2003-09-30 | 5.66% |
| 2003-06-30 | 4.91% |
| 2003-03-31 | 1.59% |
| 2002-12-31 | 6.43% |
| 2002-09-30 | 5.37% |
